HopeStage
Back to all studies
CompletedNCT07628153

Mindfulness and Biofeedback for Anxiety Disorders

Medication studyAges 19–74Russia
The study in practice

Understand this study

Who was this study for?

This study was for people with anxiety. Listed age limits: 19 years to 74 years. Other eligibility criteria applied.

Listed locations
MoscowSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: July 11, 2022
Recruitment status
Completed
Enrollment listed in the registry
188
Sponsor
I.M. Sechenov First Moscow State Medical University
Sponsor type
University
Study type
Drug
Intervention type
Combination product, Device, Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Russia
Age range
From 19 Years to 74 Years
Official registry ID
NCT07628153
Official title
Show the full official title

Development of Mindfulness Through Adaptive Biofeedback Methods in the Treatment of Anxiety Disorders: Randomized Controlled Trial

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Moscow, Russia · Russia

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is I.M. Sechenov First Moscow State Medical University, a university.

Did this study involve medication?

Yes. The study involved medication, including Escitalopram 10 mg/day.

Who was this study for?

This study was for people with anxiety. Listed age limits: 19 years to 74 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies